Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Exanthema × Hydrocortisone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 27 Leukemia 23 Prostatic Neoplasms 11 Lymphoma 11 Burkitt Lymphoma 8 Lymphoma, Large B-Cell, Diffuse 4 Myelodysplastic Syndromes 3 Lymphoma, Non-Hodgkin 3 Lymphoma, Large-Cell, Immunoblastic 3 Leukemia, Myeloid, Acute 3 Leukemia, Biphenotypic, Acute 3 Dendritic Cell Sarcoma, Interdigitating 3 Anemia, Refractory, with Excess of Blasts 3 Recurrence 2 Multiple Myeloma 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large-Cell, Anaplastic 2 Lymphoma, Follicular 2 Leukemia, Myelomonocytic, Chronic 2 Hodgkin Disease 2 Anemia, Refractory 2 Stomatitis 1 Rhabdoid Tumor 1 Pituitary Neoplasms 1 Pituitary Diseases 1 Pancreatic Neoplasms 1 Oral Ulcer 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Myeloproliferative Disorders 1

Interventions

dexpanthenol 1 Triamcinolone Acetonide 1 Tetracycline 1 Provitamins 1 Prednisone 1 Panitumumab 1 Minocycline 1 Irinotecan 1 IFL protocol 1 Hydrocortisone 1 Gels 1 Erlotinib Hydrochloride 1 Doxycycline 1 Dapsone 1 Clindamycin 1 Anti-Bacterial Agents 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡